Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors

NCT06431594 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06431594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06431594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Subjects With Advanced Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Recruiting
Start date
July 2, 2024
Completion date
December 31, 2029
Enrollment
675 (estimated)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, solid tumors